Sermorelin: A Research Overview of a Growth Hormone-Releasing Hormone Analog

Sermorelin is a synthetic peptide corresponding to the first 29 amino acids of endogenous human growth hormone-releasing hormone (GHRH). It is classified as a GHRH analog and is widely employed as a research tool to study the regulation of growth hormone (GH) secretion from the anterior pituitary. Unlike full-length GHRH (1-44), sermorelin retains the minimal sequence required for full biological activity at the GHRH receptor.

Mechanistically, sermorelin binds to the GHRH receptor (GHRHR), a class B G protein-coupled receptor expressed on pituitary somatotrophs. Receptor activation stimulates adenylyl cyclase, increases intracellular cyclic AMP, and triggers calcium influx, leading to the exocytosis of GH-containing secretory granules. In vitro, sermorelin has been shown to dose-dependently stimulate GH release from cultured pituitary cells. In vivo, its effects on GH secretion are influenced by somatostatin tone, nutritional status, and other neuroendocrine factors.

In research settings, sermorelin is used to probe somatotropic axis function, including studies of GH pulsatility, feedback regulation by insulin-like growth factor-1 (IGF-1), and age-related changes in GH secretion. It has also been employed in preclinical models to investigate conditions associated with GH deficiency or excess. Because sermorelin is a peptide, it is typically administered parenterally in animal studies; oral bioavailability is negligible due to proteolytic degradation.

It is important to note that sermorelin is not approved by regulatory agencies for human therapeutic use in most jurisdictions, and its clinical status varies. All information presented here is for research and educational purposes only. This overview does not recommend or endorse any human use, dosage, or clinical application. Researchers should consult institutional guidelines and applicable regulations when designing studies involving sermorelin.